Bristol-myers Squibb Compnay

Viiv Healthcare UK (no.5) Limited

Other

Viiv Healthcare UK Limited

John A Bender

John F Kadow

Piyasena Hewawasam

Kap-Sun Yeung

Zhong Yang

Nicholas A Meanwell

Makonen Belema

Robert G Gentles

Katharine A Grant-Young

Ying Han

Brett R Beno

Min Ding

Kyle E Parcella

Andrew Nickel

Omar D Lopez

Gan Wang

Thomas W Hudyma

Xiaofan Zheng

Yong Tu

Tao Wang

Zhongxing Zhang

Van N Nguyen

Jeffrey Lee Romine

Denis R St Laurent

Owen Brendan Wallace

Alan Xiangdong Wang

Annapurna Pendri

Louis Stanley Chupak

Rico Lavoie

Qi Chen

Richard Pracitto

B Narasimhulu Naidu

Lawrence B Snyder

Mark George Saulnier

Manoj Patel

Scott W Martin

Kevin M Peese

Ramkumar Rajamani

Carl P Bergstrom

Guo Li

Ningning Xu

Selvakumar Kumaravel

Christiana Iwuagwu

Robert A Fridell

Lawrence G Hamann

Andrew Charles Good

Edward H Ruediger

Alicia Regueiro-Ren

Zhiwei Yin

Eric P Gillis

Carol Bachand

David Bertil Frennesson

Kyle J Eastman

Manoranjan Panda

Michael S Bowsher

Srinivasan Thangathirupathy

Michael J Smith

Pulicharla Nagalakshmi

Rajesh Onkardas Bora

Shirong Zhu

Barry L Johnson

Mallikarjuna Rao Mettu

Jayne Kapur

Shilpa Maheshwarappa Holehatti

Suresh Babu

John A Easter

Bao-Ning Su

Denis R STLAURENT

Piyasena Hewasam

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: 

4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth. 

Inhibitors of human immunodeficiency virus replication

Compounds of Formula I with activity against HIV, including pharmaceutical compositions and methods for using these compounds in treating human immunodeficiency virus (HIV) infection, are set forth: 

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

Compounds of Formula I, including pharmaceutically acceptable salts thereof: I useful as HIV attachment inhibitors. 

2-keto amide derivatives as HIV attachment inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds. 

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. 

Compounds for the treatment of hepatitis C

This disclosure concerns novel compounds of Formula (I) or as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds. 

Growing community of inventors

Middletown, CT, United States of America

John A Bender